

June 21, 2024

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We refer to our earlier communication dated November 16, 2023.

We wish to further update that AstraZeneca Pharma India Limited (Company) has completed the exploration phase for search of a buyer who could act as a Contract Manufacturing Organisation and was unable to find a suitable one. The Company will now explore a buyer for its manufacturing site and exit in due course.

The Company remains committed to advance access to innovative medicines in India, with a clear ambition to be pioneers in science, lead in specialist disease areas, and transform patient outcomes. The Company is fully cognizant of the impact this change can bring and its first responsibility will be towards its employees and meeting the needs of its patients by ensuring an uninterrupted supply of medicines.

Thanking You,

For **AstraZeneca Pharma India Limited**

Manasa. R
Company Secretary